The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)

✍ Scribed by A. Nademanee; H. Fung; A. Molina; A. Krishnan; R. Rodriguez; L. Popplewell; R.T. Spielberger; M. O’Donnell; D. Snyder; P. Parker; A. Stein; N. Kogut; P. Falk; F. Sahebi; J. Zain; W. Saville; A. Raubitschek; S.J. Forman

• Book ID: 116277654
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 56 KB
• Volume: 10
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2003.12.117